Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-04

Study Completion Date

2019-04-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of the Alpha AMS Subretinal Implant

NCT02720640

Retinitis Pigmentosa

COMPLETED NA

Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

NCT01024803

Retinitis Pigmentosa Retinal Degeneration

COMPLETED NA

Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

NCT01497379

Retinal Degeneration Retinitis Pigmentosa

COMPLETED NA

Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors

NCT00515814

Retinitis Pigmentosa

COMPLETED NA

Optical Coherence Tomography Angiography Examinations in Chronic Retinal Artery Occlusion

NCT03357146

Retinal Artery Occlusion

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life. In addition, the study will provide additional information about the safety and efficacy of the CE-certified RETINA IMPLANT Alpha AMS. In several studies it has been shown that patients who received this subretinal implant regain visual function to a certain extent and that its use is safe. So far, all assessments of patients with the RETINA IMPLANT Alpha AMS have been done in a controlled environment within the scope of interventional studies where the benefit in daily life has been assessed anecdotally only. Currently, there is no standard method available for an objective assessment of the impact of such devices in daily life of these patients. Hence, the aim of this study is to further assess the impact in daily life with a combination of already validated and newly developed assessments and questionnaires.

This study adheres to the tenets of the Declaration of Helsinki.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Degeneration Inherited Retinal Dystrophy Primarily Involving Sensory Retina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RETINA IMPLANT Alpha AMS

All participants receive the subretinal device RETINA IMPLANT Alpha AMS

Group Type EXPERIMENTAL

RETINA IMPLANT Alpha AMS

Intervention Type DEVICE

Implantation of the subretinal RETINA IMPLANT Alpha AMS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RETINA IMPLANT Alpha AMS

Implantation of the subretinal RETINA IMPLANT Alpha AMS

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 to 78
2. Willing and able to give written informed consent
3. Hereditary retinal degeneration of the outer retinal layer i.e. photoreceptors (rods \& cones)
4. Pseudophakia or aphakia in the eye to be implanted
5. Retinal vessels with remaining perfusion, despite pathological condition
6. Layering of inner retina in the central region present, as shown by Optical Coherence Tomography (OCT)
7. Thickness of the retina sufficient for subretinal surgery as shown by OCT
8. Inner retina still functional (proven e.g. by light perception or electrically evoked phosphenes (EEP))
9. Blindness in both eyes, (no light perception or light perception only)
10. Visual acuity sufficient for reading normal print in earlier life, optically corrected
11. Period of appropriate visual functions at least 12 years / lifetime
12. Willing and able to perform study assessments and training during the full time period of 12 months
13. Motivation to get the best possible results through training and realistic expectations about these as assessed in screening interview

Exclusion Criteria

1. OCT shows significant retina edema and/or scar tissue within target region for implant
2. Heavy clumped pigmentation at posterior pole or on the planned route of the implantation
3. atrophy of optic nerve or ganglion cells degeneration
4. Any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment)
5. Deep amblyopia reported earlier in life on eye to be implanted
6. Systemic conditions that might imply considerable risks with regard to the surgical interventions and anesthesia (e.g. cardiovascular/pulmonary diseases, severe metabolic diseases)
7. Acute and severe neurological and/or psychiatric diseases
8. Hyperthyroidism or hypersensitivity to iodine
9. Hypersensitivity to fluorescent dye
10. Women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study or women unwilling to perform a pregnancy test before entering the study
11. Participation in another interventional clinical study within the past 30 days

Minimum Eligible Age

18 Years

Maximum Eligible Age

78 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No